Agenus Inc. [NASDAQ: AGEN] closed the trading session at $5.57 on 08/04/21. The day’s price range saw the stock hit a low of $5.415, while the highest price level was $5.67. The company report on August 3, 2021 that Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021.
Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 3:00 p.m. to 3:25 p.m. ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
The stocks have a year to date performance of 75.16 percent and weekly performance of 5.89 percent. The stock has been moved at 26.59 percent over the last six months. The stock has performed 3.53 percent around the most recent 30 days and changed 89.13 percent over the most recent 3-months.
If compared to the average trading volume of 4.92M shares, AGEN reached to a volume of 3900322 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Agenus Inc. [AGEN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AGEN shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AGEN stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
B. Riley FBR have made an estimate for Agenus Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 19, 2019. The new note on the price target was released on April 22, 2019, representing the official price target for Agenus Inc. stock. Previously, the target price had yet another drop from $10 to $5, while H.C. Wainwright kept a Neutral rating on AGEN stock.
The Average True Range (ATR) for Agenus Inc. is set at 0.23, with the Price to Sales ratio for AGEN stock in the period of the last 12 months amounting to 14.64.
AGEN stock trade performance evaluation
Agenus Inc. [AGEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.89. With this latest performance, AGEN shares gained by 3.53% in over the last four-week period, additionally plugging by 26.59% over the last 6 months – not to mention a rise of 65.28% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AGEN stock in for the last two-week period is set at 58.55, with the RSI for the last a single of trading hit 59.92, and the three-weeks RSI is set at 59.38 for Agenus Inc. [AGEN]. The present Moving Average for the last 50 days of trading for this stock 5.14, while it was recorded at 5.34 for the last single week of trading, and 3.93 for the last 200 days.
Agenus Inc. [AGEN]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Agenus Inc. [AGEN] shares currently have an operating margin of -340.25. Agenus Inc.’s Net Margin is presently recorded at -434.14.
Reflecting on the efficiency of the workforce at the company, Agenus Inc. [AGEN] managed to generate an average of -$543,170 per employee. Receivables Turnover for the company is 35.49 with a Total Asset Turnover recorded at a value of 0.27.Agenus Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.00.
Agenus Inc. [AGEN]: Insider Ownership positions
There are presently around $644 million, or 52.50% of AGEN stock, in the hands of institutional investors. The top three institutional holders of AGEN stocks are: BLACKROCK INC. with ownership of 14,251,912, which is approximately -1.83% of the company’s market cap and around 0.60% of the total institutional ownership; RTW INVESTMENTS, LP, holding 13,777,244 shares of the stock with an approximate value of $76.74 million in AGEN stocks shares; and STATE STREET CORP, currently with $70.61 million in AGEN stock with ownership of nearly 23.075% of the company’s market capitalization.
Positions in Agenus Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 76 institutional holders increased their position in Agenus Inc. [NASDAQ:AGEN] by around 16,970,165 shares. Additionally, 58 investors decreased positions by around 7,683,904 shares, while 26 investors held positions by with 91,017,561 shares. The mentioned changes placed institutional holdings at 115,671,630 shares, according to the latest SEC report filing. AGEN stock had 19 new institutional investments in for a total of 6,699,488 shares, while 18 institutional investors sold positions of 468,379 shares during the same period.